NY-SODALI-&-CO
15.7.2024 13:01:31 CEST | Business Wire | Press release
Sodali & Co (the ‘Firm’), formerly Morrow Sodali, a leading global advisory firm, is proud to announce the launch of its new brand, redefining its market presence following the Firm’s rapid international expansion through a series of successful acquisitions.
The new identity recognizes the Firm’s 50-year history and unifies the compelling combination of businesses it has acquired in recent years including GPS; Di Costa Partners; Nestor Advisors; Gryphon Advisors; Citadel Magnus; FrameworkESG; HXE Partners; Powerscourt; Domestique; and Designate. Sodali & Co has the strong investment backing of its majority owner, TPG Growth, the middle market and growth equity platform of TPG, one of the largest asset managers in the world.
Sodali & Co has built an impressive global scale with a team of more than 450 employees serving over 2,000 clients. The Firm has been consistently ranked as the leading global proxy advisor in activist and merger situations. Across its three complementary practice areas of Shareholder Services, Governance & Sustainability, and Strategic Communications, each has specialties covering:
- Shareholder Services covers proxy solicitation services, capital markets intelligence, M&A advisory, fund solutions, and global debt and bondholder solutions
- Governance & Sustainability covers corporate governance, board services, sustainability advisory, and climate advisory
- Strategic Communications covers corporate communications, crisis & special situations, financial & transaction communications, investor relations, public affairs & campaigns, research, and brand & design
The new name derives from the Latin word “Sodalis,” meaning “companion,” and aligns with the Firm’s role as a trusted advisor, helping clients build stakeholder capital through navigating the complex dynamic of shareholder and wider stakeholder interests.
“By bringing together our diverse expertise under one unified entity, we are better positioned to assist our clients’ evolving needs,” said Alvise Recchi, global CEO. “No other firm combines integrated and specialist expertise in shareholder services, governance and sustainability, and strategic communications in the same way as Sodali & Co.”
“This is not just a rebrand. It represents our dedication to building a world-class advisory firm,” said Recchi. “We are unwavering in our commitment to excellence for our clients, supporting them to adapt and thrive in an increasingly volatile, uncertain, complex, and ambiguous world.”
The Sodali & Co brand will be deployed globally immediately.
ABOUT SODALI & CO
Sodali & Co advises corporate clients worldwide as they navigate the complex dynamic of shareholder and stakeholder interests. The firm supports business leaders in anticipating issues, making better, more informed decisions, and communicating more effectively to drive alignment and accelerate performance.
From headquarters in New York, London, and Sydney to offices in major capital markets, Sodali & Co serves over 2,000 corporate clients in 70 countries, across three practice areas of Shareholder Services, Governance & Sustainability, and Strategic Communications. In addition to listed and private companies, its clients include financial institutions, mutual funds, ETFs, stock exchanges, and membership associations.
For more information about Sodali & Co, please visit www.sodali.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715014030/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom